An open‐label, multi‐centre, post‐marketing study to assess the efficacy and safety of a plasma‐derived VWF/FVIII concentrate in patients with von Willebrand disease.

Autor:	Miesbach, Wolfgang, Halimeh, Susan, Platokouki, Helen, Podolak‐Dawidziak, Maria, Zdziarska, Joanna, Korczowski, Bartosz, Chowdary, Pratima, Austin, Steve, Millar, Carolyn, Alamelu, Jayanthi, Rogosch, Tobias, Pabinger, Ingrid
Předmět:	VON Willebrand disease INFORMED consent (Medical law) SURGICAL blood loss
Zdroj:	Haemophilia; Jan2024, Vol. 30 Issue 1, p236-240, 5p
Abstrakt:	This article presents the findings of a post-marketing study on the use of a plasma-derived von Willebrand Factor (VWF)/factor VIII (FVIII) concentrate for the treatment of von Willebrand disease (VWD). VWD is a common inherited bleeding disorder. The study included patients of all ages with severe types of VWD. The results showed that the treatment was well-tolerated and provided effective control of bleeding for both adult and pediatric patients. The study supports the use of this treatment for VWD. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text